Arrowhead Research | ARWR - Ordinary Share Capital



Arrowhead Research reported $138.14M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Agios Pharmaceuticals USD 58.04M 57.96M Jun/2025
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
Arrowhead Research USD 138.14M 137.91M Jun/2025
Incyte USD 194.12M 193.93M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
Ligand Pharmaceuticals USD 19.41M 19.39M Jun/2025
Merck USD 1.79B 0 Mar/2025
Moderna USD 389M 388.96M Jun/2025
Novartis USD 793M 0 Dec/2024
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
TG Therapeutics USD 158.02M 157.87M Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025
Xencor USD 71.3M 70.58M Jun/2025